Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F07%3A00022796" target="_blank" >RIV/00216224:14110/07:00022796 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)
Original language description
i) Introduction: The aim of this study is to investigate if Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiplemyeloma (MM) treated by conventional or myeloablastive treatment: deletion of RB gene (13q14), deletion of p53 (17p13), amplification of CKS1B gene (1q21) and translocation t(4;14). ii) Material and Methods: We have identified monotypic plasma cells andstudied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Up-to-date group of 18 patients (pts.) has following characteristic: 67% of men, median age 62,5 years (44,4-77,9). 50% (9 pts.) were instage IIIA, 28% (5 pts.) in IIA and 22% (4 pts.) in IA. 61% (11 pts.) were in first relapse, 22% (4 pts.) were in second relapse. The others 17% (3 pts.) were in third relapse. Treatment with Velcade based regimens was continued for up to
Czech name
Prognostický vliv cytogenetických abnormalit u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade)
Czech description
Práce pojednává o významu detekce chromozomálních aberací u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade).
Classification
Type
D - Article in proceedings
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LC06027" target="_blank" >LC06027: University Research Centre - Czech Myeloma Group</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2007
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Article name in the collection
Hematologica/The Hematology Journal
ISBN
—
ISSN
0390-6078
e-ISSN
—
Number of pages
1
Pages from-to
165-165
Publisher name
Ferrata-Storti Foundation
Place of publication
Pavia, Italy
Event location
Kos Island, Greece
Event date
Jun 25, 2007
Type of event by nationality
WRD - Celosvětová akce
UT code for WoS article
—